Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, MD, Seiichiro Katagiri, MD, Seiichi Okabe, M.D., Yosuke Minami, MD, PhD, Tomoki Naoe, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1298.

https://doi.org/10.1182/blood.V122.21.1298.1298

Published: 2013

Journal Articles

Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Seiichiro Katagiri, MD, Yuko Tanaka, MD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 1333.

https://doi.org/10.1182/blood.V120.21.1333.1333

Published: 2012

Journal Articles

Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Seiichiro Katagiri, MD, Yuko Tanaka, MD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 3737.

https://doi.org/10.1182/blood.V120.21.3737.3737

Published: 2012

Journal Articles

Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, M.D., Seiichiro Katagiri, M.D., Seiichi Okabe, M.D., Yosuke Minami, MD, PhD, Tomoki Naoe, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 531.

https://doi.org/10.1182/blood.V120.21.531.531

Published: 2012

Journal Articles

Targeting the Hedgehog Signaling Pathway in Therapy-Resistant BCR-ABL1 Positive Leukemia with Ponatinib

Seiichiro Katagiri, M.D., Tetsuzo Tauchi, M.D., Seiichi Okabe, M.D., Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, DMSci, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 63.

https://doi.org/10.1182/blood.V118.21.63.63

Published: 2011

Journal Articles

Combined Effects of a Pan-ABL1 Kinase Inhibitor, Ponatinib and Dasatinib Against T315I Mutant Forms of BCR-ABL1: In Vitro and In Vivo Studies

Tetsuzo Tauchi, M.D., Seiichiro Katagiri, M.D., Seiichi Okabe, M.D., Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, DMSci, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 2482.

https://doi.org/10.1182/blood.V118.21.2482.2482

Published: 2011

Journal Articles

Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 1403.

https://doi.org/10.1182/blood.V118.21.1403.1403

Published: 2011

Journal Articles

Efficacy of Ponatinib Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 4413.

https://doi.org/10.1182/blood.V118.21.4413.4413

Published: 2011

Journal Articles

Combined Effects of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib In a Random Mutagenesis Screen

Tetsuzo Tauchi, M.D., Seiichi Okabe, M.D., Eishi Ashihara, M.D., Shinya Kimura, M.D., Taira Maekawa, M.D., Kazuma Ohyashiki, M.D.

Blood (2010) 116 (21): 595.

https://doi.org/10.1182/blood.V116.21.595.595

Published: 2010

Journal Articles

Activity of the Histone Deacetylase Inhibitor, Vorinostat, Against BCR-ABL Positive Leukemia Cells with Random Mutagenesis and In Combination with Nilotinib

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, DMSci, Kazuma Ohyashiki, MD, PhD

Blood (2010) 116 (21): 4460.

https://doi.org/10.1182/blood.V116.21.4460.4460

Published: 2010

Journal Articles

GDC-0449, the Small Molecule Inhibitor of Hedgehog-Gli Pathway for the Treatment of BCR-ABL Positive Leukemia Cells and In Combination with Dasatinib

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Kazuma Ohyashiki, MD, PhD

Blood (2010) 116 (21): 2136.

https://doi.org/10.1182/blood.V116.21.2136.2136

Published: 2010

NARROW

Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells

Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells

Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Targeting the Hedgehog Signaling Pathway in Therapy-Resistant BCR-ABL1 Positive Leukemia with Ponatinib

Combined Effects of a Pan-ABL1 Kinase Inhibitor, Ponatinib and Dasatinib Against T315I Mutant Forms of BCR-ABL1: In Vitro and In Vivo Studies

Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells

Efficacy of Ponatinib Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells

Combined Effects of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib In a Random Mutagenesis Screen

Activity of the Histone Deacetylase Inhibitor, Vorinostat, Against BCR-ABL Positive Leukemia Cells with Random Mutagenesis and In Combination with Nilotinib

GDC-0449, the Small Molecule Inhibitor of Hedgehog-Gli Pathway for the Treatment of BCR-ABL Positive Leukemia Cells and In Combination with Dasatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only